TP53 Variants Increase Risk for Pediatric ALL, Adverse Treatment Outcomes
Children with TP53 pathogenic variants were more likely to both develop acute lymphoblastic leukemia, as well as secondary cancers later on, according to a recent analysis.
Source: OncLive